Table 1 Association of miR-3662 expression with various clinical parameters in HCC patients
Clinicopathological features | n | Low miR-3662 | High miR-3662 | P |
|---|---|---|---|---|
Age (years) | 0.567 | |||
≤60 | 21 | 12 (57.1%) | 9 (42.9%) | |
>60 | 29 | 13 (44.8%) | 16 (55.2%) | |
Gender | 1.000 | |||
Female | 15 | 7 (46.7%) | 8 (53.3%) | |
Male | 35 | 18 (51.4%) | 17 (48.6%) | |
Liver cirrhosis | 0.667 | |||
No | 6 | 4 (66.7%) | 2 (33.3%) | |
Yes | 44 | 21 (47.7%) | 23 (52.3%) | |
HBsAg status | 1.000 | |||
Negative | 7 | 3 (42.9%) | 4 (57.1%) | |
Positive | 43 | 22 (51.2%) | 21 (48.8%) | |
α-fetoprotein (ng/ml) | 0.345 | |||
≤20 | 14 | 5 (35.7%) | 9 (64.3%) | |
>20 | 36 | 20 (55.6%) | 16 (44.4%) | |
Tumor size (cm) | 0.022 | |||
≤5 | 23 | 7 (30.4%) | 16 (69.6%) | |
>5 | 27 | 18 (66.7%) | 9 (33.3%) | |
Tumor multiplicity | 0.019 | |||
Single | 31 | 11 (35.5%) | 20 (64.5%) | |
Multiple | 19 | 14 (73.7%) | 5 (26.3%) | |
Edmondson grade | 0.032 | |||
I–II | 34 | 13 (38.2%) | 21 (61.8%) | |
III–IV | 16 | 12 (75.0%) | 4 (25.0%) | |
Tumor-node-metastasis stage | 0.004 | |||
I–II | 29 | 9 (31.0%) | 20 (69.0%) | |
III | 21 | 16 (76.2%) | 5 (23.8%) |
